anti-Claudin18.2 antibody-drug conjugate IBI343

{
  "id": "MLC-T-ONC-010490",
  "term": "anti-Claudin18.2 antibody-drug conjugate IBI343",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration, anti-CLDN18.2 ADC IBI343 specifically targets and binds to CLDN18.2 expressed on tumor cells. Upon internalization, the cytotoxic agent induces apoptosis in CLDN18.2-expressing tumor cells through an as of yet unidentified mechanism of action (MoA). CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.",
  "synonyms": [
    "ADC IBI343",
    "anti-CLDN18.2 ADC IBI343"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-claudin18-2-antibody-drug-conjugate-ibi343/"
}